← Leaderboards
Joshua D Brody
Icahn School Of Medicine At Mount Sinai
$3,349,866
Attributed
$3,349,866
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $387.7K · FY2009–25$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,349,866 · 3
By mechanism
R37$2,263,440 · 1
R00$739,530 · 1
K99$346,896 · 1
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Darrell J Irvine$37,519,809
- Gabrielle Lubitz$138,620
- Brian D Brown$18,622,393
- Miriam Merad$28,468,631
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorLymphomaT-LymphocyteResponseDisease RemissionNon-Hodgkin&AposCytokinePre-Clinical ModelImmune SystemT Cell ResponseImmunotherapyAnimal ModelResistanceMolecularMediatingPreventAgonistDendritic CellsCross Reacting Material 197Antigen-Specific T CellsCross-PrimingImmune Checkpoint BlockadeImmunologic MonitoringClinical Remission
Grant awards (11)
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination$351,924
R37 · FY2025 · CA · contact PI
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination$368,346
R37 · FY2024 · CA · contact PI
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination$379,977
R37 · FY2023 · CA · contact PI
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination$387,731
R37 · FY2022 · CA · contact PI
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination$387,731
R37 · FY2021 · CA · contact PI
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination$387,731
R37 · FY2020 · CA · contact PI
Immunotransplant to Mantle Cell Lymphoma: Immune Response and Clinical Outcomes$241,530
R00 · FY2014 · CA · contact PI
Immunotransplant to Mantle Cell Lymphoma: Immune Response and Clinical Outcomes$249,000
R00 · FY2013 · CA · contact PI
Immunotransplant to Mantle Cell Lymphoma: Immune Response and Clinical Outcomes$249,000
R00 · FY2012 · CA · contact PI
Immunotransplant to Treat Lymphoma: Pre-Clinical Model to Clinical Trial Design$173,448
K99 · FY2010 · CA · contact PI
Immunotransplant to Treat Lymphoma: Pre-Clinical Model to Clinical Trial Design$173,448
K99 · FY2009 · CA · contact PI